Dasolampanel (

INN Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...

, USAN, code name NGX-426) is an orally bioavailable analog of

tezampanel Tezampanel (INN, USAN) (code names LY-293,558, NGX-424) is a drug originally developed by Eli Lilly which acts as a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family, with selectivity for the G ...

and thereby

competitive antagonist A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist. Antagonist drugs interfere in the natural operation of recep ...

of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/ Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and

migraine Migraine (, ) is a common neurological disorder characterized by recurrent headaches. Typically, the associated headache affects one side of the head, is pulsating in nature, may be moderate to severe in intensity, and could last from a few hou ...

. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by

intravenous injection Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutri ...

, but ultimately neither drug was ever marketed.

References

AMPA receptor antagonists Analgesics Antimigraine drugs Carboxylic acids Decahydroisoquinolines Kainate receptor antagonists Chlorobenzenes Prodrugs Tetrazoles {{Analgesic-stub

See also

References